Table 1.

MSCs therapy indications and infusion scheme.

	Previous treatments	Number of patients N (%)	MSCs infusion scheme
aGVHD	GC, ECP, RXL, MMF, infliximab, sirolimus	13 (43.3)	4 infusions on days: +1, +4, +11, +18
cGVHD	GC, ECP, RXL	5 (16.7)
Graf failure	1–3 previous HSCT	2 (6.7)	2 infusions on days: +1 (co-infusion with HSCT), +15
Poor graft function	Eltrombopag, CD34 boost	6 (20)	2 infusions on days: +1 (co-infusion with CD34 boost), +15
Hemorrhagic cystitis	Cydofovir, intravesical: hyaluroic acid, E-aminocaproic acid/urokinase	4 (13.3)	3–4 infusions on days: +1, +7, +14, (+18)
All	NA	30	NA

GC, glucocorticoids; ECP, extracorporeal photopheresis; RXL, ruxolitinib; MMF, mycophenolate; HSCT, hematopoietic stem cell transplant; aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; NA, not applicable.